MX2022006304A - Composiciones y metodos para inhibir la actividad biologica de biomoleculas solubles. - Google Patents
Composiciones y metodos para inhibir la actividad biologica de biomoleculas solubles.Info
- Publication number
- MX2022006304A MX2022006304A MX2022006304A MX2022006304A MX2022006304A MX 2022006304 A MX2022006304 A MX 2022006304A MX 2022006304 A MX2022006304 A MX 2022006304A MX 2022006304 A MX2022006304 A MX 2022006304A MX 2022006304 A MX2022006304 A MX 2022006304A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- biological activity
- inhibiting
- methods
- soluble biomolecules
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
- A61K47/6937—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol the polymer being PLGA, PLA or polyglycolic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Abstract
La descripción provee, entre otras cosas, composiciones que se unen a, e inhiben, la actividad biológica de biomoléculas solubles, así como composiciones farmacéuticas de las mismas. También en este documento se provee una serie de aplicaciones (por ejemplo, aplicaciones terapéuticas) en las cuales las composiciones son útiles.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462059628P | 2014-10-03 | 2014-10-03 | |
US201562198519P | 2015-07-29 | 2015-07-29 | |
US201562198541P | 2015-07-29 | 2015-07-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022006304A true MX2022006304A (es) | 2022-06-22 |
Family
ID=55631617
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017003903A MX2017003903A (es) | 2014-10-03 | 2015-10-02 | Composiciones y metodos para inhibir la actividad biologica de biomoleculas solubles. |
MX2022006304A MX2022006304A (es) | 2014-10-03 | 2017-03-24 | Composiciones y metodos para inhibir la actividad biologica de biomoleculas solubles. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017003903A MX2017003903A (es) | 2014-10-03 | 2015-10-02 | Composiciones y metodos para inhibir la actividad biologica de biomoleculas solubles. |
Country Status (14)
Country | Link |
---|---|
US (5) | US9623081B2 (es) |
EP (1) | EP3215176A4 (es) |
JP (3) | JP6876608B2 (es) |
KR (2) | KR102510540B1 (es) |
CN (4) | CN115957347A (es) |
AU (2) | AU2015327928A1 (es) |
BR (1) | BR112017006552A2 (es) |
CA (1) | CA2962251A1 (es) |
EA (1) | EA035898B1 (es) |
HK (1) | HK1252911A1 (es) |
IL (1) | IL251232B (es) |
MX (2) | MX2017003903A (es) |
SG (1) | SG11201702304UA (es) |
WO (1) | WO2016054522A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3097420A4 (en) * | 2014-01-24 | 2018-01-17 | Ntercept, LLC | Methods and compositions for immune dis-inhibition |
JP6876608B2 (ja) | 2014-10-03 | 2021-05-26 | ナノティックス,エルエルシー | 可溶性生体分子の生物学的活性を阻害するための組成物及び方法 |
AU2016285868B2 (en) * | 2015-06-30 | 2021-11-11 | Nanotics, Llc | Compositions and methods related to scavenger particles |
CN114146056A (zh) * | 2015-07-29 | 2022-03-08 | 纳米提克斯有限责任公司 | 用于清除可溶性生物分子的模块化组合物及其相关方法 |
WO2018129188A1 (en) * | 2017-01-04 | 2018-07-12 | Nanotics, Llc | Methods for assembling scavenging particles |
JP2020504177A (ja) * | 2017-01-04 | 2020-02-06 | ナノティックス,エルエルシー | 捕捉粒子をアセンブルするための方法 |
CN109173755B (zh) * | 2018-09-19 | 2020-04-03 | 苏州大学 | 超疏水多功能膜及其制备方法与在油水分离中的应用 |
CN113272320A (zh) * | 2018-11-19 | 2021-08-17 | 得克萨斯大学体系董事会 | 自杀基因 |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3710795A (en) | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
US4863457A (en) | 1986-11-24 | 1989-09-05 | Lee David A | Drug delivery device |
US5164188A (en) | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
KR0185215B1 (ko) | 1990-11-30 | 1999-05-01 | 요시다 쇼오지 | 서방성 안구삽입용 약제 |
US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
PT1498427E (pt) | 1992-08-21 | 2010-03-22 | Univ Bruxelles | Imunoglobulinas desprovidas de cadeias leves |
DK0698097T3 (da) | 1993-04-29 | 2001-10-08 | Unilever Nv | Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde |
US5814272A (en) | 1996-02-21 | 1998-09-29 | Millipore Corporation | Method for forming dendritic metal particles |
US7070590B1 (en) | 1996-07-02 | 2006-07-04 | Massachusetts Institute Of Technology | Microchip drug delivery devices |
US6620382B1 (en) | 1998-05-22 | 2003-09-16 | Biopheresis Technologies, Llc. | Method and compositions for treatment of cancers |
US8197430B1 (en) | 1998-05-22 | 2012-06-12 | Biopheresis Technologies, Inc. | Method and system to remove cytokine inhibitor in patients |
AU783238B2 (en) | 1999-11-10 | 2005-10-06 | Innatus Corporation | Method and system to remove cytokine inhibitor in patients |
EP1174129A1 (en) | 2000-07-17 | 2002-01-23 | Zenner, Hans Peter, Prof. Dr. med. | Use of a matrix-metalloprotease inhibitor for the treatment of cancer |
JP2002248682A (ja) * | 2001-02-26 | 2002-09-03 | Neoex Lab Inc | 表皮装着用の型、及び表皮装着方法 |
DE10144252A1 (de) * | 2001-08-31 | 2003-03-27 | Fraunhofer Ges Forschung | Nanopartikel mit daran immobilisiertem biologisch aktivem TNF |
DE10144251A1 (de) * | 2001-08-31 | 2003-03-27 | Fraunhofer Ges Forschung | Vorrichtung für die gerichtete Immobilisierung von Proteinen |
ES2425013T3 (es) | 2002-06-12 | 2013-10-10 | Symphony Evolution, Inc. | Inhibidores de ADAM-10 humana |
AU2003279070A1 (en) | 2002-09-30 | 2004-04-23 | Acusphere Inc | Sustained release porous microparticles for inhalation |
AU2003295471B2 (en) | 2002-11-15 | 2011-08-25 | Genmab A/S | Human monoclonal antibodies against CD25 |
US7297298B2 (en) | 2002-12-25 | 2007-11-20 | Fujifilm Corporation | Nano-particles and process for producing nano-particles |
WO2004071641A2 (en) * | 2003-02-10 | 2004-08-26 | Pointilliste, Inc. | Self-assembling arrays and uses thereof |
US8685435B2 (en) | 2004-04-30 | 2014-04-01 | Allergan, Inc. | Extended release biodegradable ocular implants |
SI1949915T1 (sl) | 2004-04-30 | 2012-12-31 | Biopheresis Technologies, Inc. | Postopek in sistem za odstranitev topnih TNFR1, TNFR2 in IL2R pri pacientih |
JP2008507529A (ja) | 2004-07-22 | 2008-03-13 | アーリー ディテクション, エルエルシー | 抗サイトカインレセプター抗体を用いる診断のための方法 |
CN101123990A (zh) | 2004-10-01 | 2008-02-13 | Mida科技有限公司 | 包含抗原和佐剂的纳米颗粒,和免疫原性结构 |
WO2006086428A2 (en) * | 2005-02-08 | 2006-08-17 | Board Of Regents, The University Of Texas System | Particles for inactivating toxins |
US20110097277A1 (en) | 2005-08-25 | 2011-04-28 | University Of Washington | Particles coated with zwitterionic polymers |
FR2895289B1 (fr) | 2005-12-23 | 2009-08-21 | Centre Nat Rech Scient | Synthese de particules dans des structures dendritiques en milieux fluides supercritiques |
WO2007095162A2 (en) | 2006-02-13 | 2007-08-23 | Advanced Materials Technology, Inc. | Porous microparticles solid cores |
WO2008021908A2 (en) | 2006-08-08 | 2008-02-21 | Board Of Regents Of The University Of Texas | Multistage delivery of active agents |
US20080075690A1 (en) | 2006-09-22 | 2008-03-27 | Mark Douglas Howell | Method for enhancing immune responses in mammals |
WO2008041774A1 (fr) * | 2006-10-02 | 2008-04-10 | National Institute For Materials Science | Préparation à libération prolongée capable de conduction osseuse |
WO2008127515A1 (en) * | 2007-03-01 | 2008-10-23 | Cytologic, Inc. | Compositions and method for enhancing immune responses in mammals |
CN101903290B (zh) | 2007-08-31 | 2013-01-09 | 混合硅晶科技公司 | Peg包覆的核-壳二氧化硅纳米颗粒及其制备方法和应用 |
EP2033660A1 (en) | 2007-09-05 | 2009-03-11 | Freie Universität Berlin | Functionalized nanoparticles for the inhibition of selectin-mediated cell adhesion |
US8586096B2 (en) | 2007-10-01 | 2013-11-19 | The Curators Of The University Of Missouri | Soy or lentil stabilized gold nanoparticles and method for making same |
US8906356B2 (en) | 2007-11-05 | 2014-12-09 | Massachusetts Institute Of Technology | Mutant interleukin-2 (IL-2) polypeptides |
WO2010042555A2 (en) | 2008-10-06 | 2010-04-15 | The Brigham And Women's Hospital, Inc. | Particles with multiple functionalized surface domains |
US8574549B2 (en) | 2008-12-29 | 2013-11-05 | General Electric Company | Nanoparticle contrast agents for diagnostic imaging |
US9399075B2 (en) | 2008-12-29 | 2016-07-26 | General Electric Company | Nanoparticle contrast agents for diagnostic imaging |
WO2010084088A2 (en) | 2009-01-21 | 2010-07-29 | Basf Se | Starch nanoparticles for drug delivery systems |
US20120108787A1 (en) * | 2009-02-26 | 2012-05-03 | Nubiome, Inc. | Immobilization Particles for Removal of Microorganisms and/or Chemicals |
WO2010111517A1 (en) | 2009-03-25 | 2010-09-30 | Northeastern University | Stable polyelectrolyte coated nanoparticles |
RU2624506C2 (ru) | 2009-04-29 | 2017-07-04 | АМАРИН КОРПОРЕЙШН ПиЭлСи | Фармацевтические композиции, содержащие ера и сердечно-сосудистое средство, и способы их применения |
DK2449379T3 (en) | 2009-07-02 | 2017-08-28 | Sloan-Kettering Inst For Cancer Res | FLUORESCING SILICA-BASED NANOPARTICLES |
EA201290506A1 (ru) | 2009-12-16 | 2013-03-29 | Брихэм Энд Уимен'З Хоспитал, Инк. | Частицы для доставки множества агентов |
US20120141797A1 (en) | 2010-04-21 | 2012-06-07 | Brookhaven Science Associates, Llc | Zwitterion-Linker Coatings for Nano-objects in Solutions of Multivalent Counterions |
CN103124725B (zh) | 2010-05-14 | 2014-11-12 | 香港大学 | 固体负载金纳米粒子、其使用方法及其制备方法 |
ES2628351T3 (es) | 2010-10-13 | 2017-08-02 | Pharma Diagnostics Nv | Método para recubrir nanopartículas |
EP2468764A1 (en) | 2010-12-24 | 2012-06-27 | Rijksuniversiteit te Groningen | TNF family ligand variants |
KR101642903B1 (ko) | 2011-02-09 | 2016-07-27 | 한화케미칼 주식회사 | 친수성 물질이 코팅된 산화철 나노입자의 제조방법 및 이를 이용하는 자기공명영상 조영제 |
WO2012163544A1 (en) | 2011-06-01 | 2012-12-06 | Biopheresis Technologies, Inc. | Removal of soluble tumor necrosis factor receptor 2 (stnfr2) |
WO2013052167A2 (en) | 2011-06-02 | 2013-04-11 | The Regents Of The University Of California | Membrane encapsulated nanoparticles and method of use |
WO2013011764A1 (ja) | 2011-07-15 | 2013-01-24 | 国立大学法人 東京大学 | シリコンマイクロ粒子及びその合成方法 |
JP6209517B2 (ja) | 2011-08-26 | 2017-10-04 | ベコイ ナノメディシンズ リミテッドVecoy Nanomedicines Ltd. | 病原体を捕獲するための合成物および薬学的組成物 |
WO2013029278A1 (en) | 2011-09-02 | 2013-03-07 | National Center For Nanoscience And Technology | A method for preparing functionalized silicon nanoparticles |
WO2013095736A2 (en) | 2011-09-27 | 2013-06-27 | The Methodist Hospital Research Institute | Gold-in-silicon nanoassembly for thermal therapy and methods of use |
US8926994B2 (en) | 2011-12-07 | 2015-01-06 | The Methodist Hospital Research Institute | Mesoporous silicon particles for the presentation of tumor antigens and adjuvant for anti-cancer immunity |
US20130337070A1 (en) | 2012-05-25 | 2013-12-19 | University Of Central Florida Research Foundation Inc. | Coated Nanoparticle Therapy for Skin Cancer |
WO2013179143A2 (en) | 2012-06-01 | 2013-12-05 | Biopheresis Technologies, Inc. | Sensitization of cancer cells by the removal of soluble tumor necrosis factor receptors |
US10842749B2 (en) | 2012-06-12 | 2020-11-24 | The Methodist Hospital Research Institute | Compositions and methods of treating therapy resistant cancer and uses thereof |
EP2895197B1 (en) | 2012-09-12 | 2020-02-26 | Ramot at Tel-Aviv University Ltd. | Immunoparticles and methods of generating and using same |
WO2014109842A2 (en) * | 2012-11-28 | 2014-07-17 | Cytimmune Sciences, Inc. | Nanotechnology based medicine for biodefense |
US9309114B2 (en) | 2013-01-14 | 2016-04-12 | Xerox Corporation | Porous nanoparticles produced by solvent-free emulsification |
EP2968571A4 (en) | 2013-03-15 | 2016-09-07 | Psivida Inc | BIODEGRADABLE SILICONE BASED COMPOSITIONS FOR THE DELIVERY OF THERAPEUTIC AGENTS |
RU2015132626A (ru) | 2013-03-15 | 2017-04-25 | Слоун-Кеттеринг Инститьют Фо Кэнсэ Рисерч | Мультимодальные наночастицы на основе диоксида кремния |
WO2014170899A1 (en) | 2013-04-18 | 2014-10-23 | Bar-Ilan University | Systems comprising non-immunogenic and nuclease resistant nucleic acid origami devices for molecular computation |
ITMI20130631A1 (it) * | 2013-04-18 | 2014-10-19 | Consiglio Nazionale Ricerche | Metodo di realizzazione di una guida d'onda in un substrato tramite laser a femtosecondi |
US20150112842A1 (en) | 2013-10-21 | 2015-04-23 | Insurance Auto Auctions, Inc. | Parts exchange method and apparatus |
EP3097420A4 (en) * | 2014-01-24 | 2018-01-17 | Ntercept, LLC | Methods and compositions for immune dis-inhibition |
JP6876608B2 (ja) * | 2014-10-03 | 2021-05-26 | ナノティックス,エルエルシー | 可溶性生体分子の生物学的活性を阻害するための組成物及び方法 |
AU2016285868B2 (en) | 2015-06-30 | 2021-11-11 | Nanotics, Llc | Compositions and methods related to scavenger particles |
CN114146056A (zh) | 2015-07-29 | 2022-03-08 | 纳米提克斯有限责任公司 | 用于清除可溶性生物分子的模块化组合物及其相关方法 |
US20170056327A1 (en) | 2015-08-25 | 2017-03-02 | The Methodist Hospital | Micro/nano composite drug delivery formulations and uses thereof |
WO2017176762A1 (en) | 2016-04-06 | 2017-10-12 | Nanotics, Llc | Particles comprising subparticles or nucleic acid scaffolds |
JP2020504177A (ja) | 2017-01-04 | 2020-02-06 | ナノティックス,エルエルシー | 捕捉粒子をアセンブルするための方法 |
WO2018129188A1 (en) | 2017-01-04 | 2018-07-12 | Nanotics, Llc | Methods for assembling scavenging particles |
-
2015
- 2015-10-02 JP JP2017538165A patent/JP6876608B2/ja active Active
- 2015-10-02 WO PCT/US2015/053748 patent/WO2016054522A1/en active Application Filing
- 2015-10-02 MX MX2017003903A patent/MX2017003903A/es unknown
- 2015-10-02 KR KR1020177011587A patent/KR102510540B1/ko active IP Right Grant
- 2015-10-02 CN CN202310118475.XA patent/CN115957347A/zh active Pending
- 2015-10-02 US US14/873,847 patent/US9623081B2/en active Active
- 2015-10-02 BR BR112017006552A patent/BR112017006552A2/pt active Search and Examination
- 2015-10-02 EA EA201790773A patent/EA035898B1/ru not_active IP Right Cessation
- 2015-10-02 EP EP15845555.0A patent/EP3215176A4/en active Pending
- 2015-10-02 CA CA2962251A patent/CA2962251A1/en active Pending
- 2015-10-02 KR KR1020237008615A patent/KR20230042391A/ko not_active Application Discontinuation
- 2015-10-02 CN CN202310092283.6A patent/CN115990272A/zh active Pending
- 2015-10-02 CN CN201580065861.0A patent/CN106999550B/zh active Active
- 2015-10-02 SG SG11201702304UA patent/SG11201702304UA/en unknown
- 2015-10-02 CN CN201710931432.8A patent/CN107837389B/zh active Active
- 2015-10-02 AU AU2015327928A patent/AU2015327928A1/en not_active Abandoned
-
2017
- 2017-03-06 US US15/450,769 patent/US9907831B2/en active Active
- 2017-03-16 IL IL251232A patent/IL251232B/en unknown
- 2017-03-24 MX MX2022006304A patent/MX2022006304A/es unknown
-
2018
- 2018-03-01 US US15/909,820 patent/US10420817B2/en active Active
- 2018-09-24 HK HK18112259.1A patent/HK1252911A1/zh unknown
-
2019
- 2019-08-07 US US16/534,428 patent/US10888602B2/en active Active
-
2020
- 2020-12-10 US US17/118,013 patent/US11771744B2/en active Active
-
2021
- 2021-02-08 JP JP2021018410A patent/JP2021098696A/ja active Pending
- 2021-07-14 AU AU2021205051A patent/AU2021205051A1/en active Pending
-
2022
- 2022-06-01 JP JP2022089328A patent/JP2022126668A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023005262A (es) | Composiciones y metodos relacionados con particulas depuradoras. | |
PH12017502255A1 (en) | Nrf2 regulators | |
MX2022006304A (es) | Composiciones y metodos para inhibir la actividad biologica de biomoleculas solubles. | |
PH12018500899A1 (en) | Compositions and methods for inhibiting arginase activity | |
PH12017500408B1 (en) | Heteroaryl compounds as btk inhibitors and uses thereof | |
MX2018008052A (es) | Inhibidores de desmetilasa especifica de lisina 1 (lsd1). | |
MX2018002315A (es) | Anticuerpos anti muerte programada 1 (pd 1) y metodos de uso de los mismos. | |
PH12016501151A1 (en) | Nrf2 regulators | |
MX2016016666A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
MX2017006217A (es) | Polinucleotidos moduladores. | |
MX2016015093A (es) | Derivados de acido boronico y sus usos terapeuticos. | |
MX2017004838A (es) | Composiciones de interleucina-15 y usos de estas. | |
TW201613901A (en) | New compounds | |
MY187540A (en) | Compounds active towards bromodomains | |
MX2016008448A (es) | Conjugados de var2csa-farmaco. | |
EA039598B9 (ru) | Соединение, нацеленное на ил-23а и фно-альфа, и его применение | |
CL2016003074A1 (es) | Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer. | |
MX2016014559A (es) | Compuestos para el tratamiento de cancer. | |
TR201910866T4 (tr) | Kanser tedavisi için birleşik preparasyonlar. | |
MX2017007377A (es) | Compuestos organicos. | |
PH12017500459A1 (en) | Azetidinyloxyphenylpyrrolidine compounds | |
MX2017012596A (es) | Una composicion farmaceutica y el uso de la misma. | |
PH12017500348A1 (en) | Tetrahydroquinoline derivatives as bromodomain inhibitors | |
MX2017009608A (es) | Compuestos anticancerigenos. | |
MX371158B (es) | Compuestos inhibidores de pde2. |